Ligand Pharmaceuticals Incorporated provided earnings guidance for the year 2024. For the year, the company expects total revenue of $130 million to $142 million, comprised of $90 million to $95 million from royalties, $25 million to $27 million from sales of Captisol and $15 million to $20 million from contract revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.63 USD | +10.12% | +13.55% | +13.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.55% | 1.31B | |
+33.40% | 700B | |
-4.88% | 358B | |
+18.87% | 330B | |
+3.39% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.62% | 161B | |
-2.16% | 157B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024